United Therapeutics (UTHR) Interest Expenses (2016 - 2025)
Historic Interest Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $3.0 million.
- United Therapeutics' Interest Expenses fell 7029.7% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 5149.7%. This contributed to the annual value of $42.9 million for FY2024, which is 2765.6% down from last year.
- Per United Therapeutics' latest filing, its Interest Expenses stood at $3.0 million for Q3 2025, which was down 7029.7% from $7.3 million recorded in Q2 2025.
- In the past 5 years, United Therapeutics' Interest Expenses registered a high of $15.6 million during Q3 2023, and its lowest value of $3.0 million during Q3 2025.
- Over the past 5 years, United Therapeutics' median Interest Expenses value was $7.9 million (recorded in 2024), while the average stood at $8.9 million.
- Its Interest Expenses has fluctuated over the past 5 years, first soared by 19361.7% in 2023, then crashed by 7029.7% in 2025.
- United Therapeutics' Interest Expenses (Quarter) stood at $4.7 million in 2021, then surged by 161.7% to $12.3 million in 2022, then grew by 22.76% to $15.1 million in 2023, then tumbled by 47.68% to $7.9 million in 2024, then crashed by 62.03% to $3.0 million in 2025.
- Its Interest Expenses stands at $3.0 million for Q3 2025, versus $7.3 million for Q2 2025 and $6.1 million for Q1 2025.